Literature DB >> 25274461

Coronary revascularization and TAVI: before, during, after or never?

C J O'Sullivan1, G G Stefanini, S Stortecky, D Tüller, S Windecker, P Wenaweser.   

Abstract

Aortic valve stenosis and coronary artery disease (CAD) frequently coexist in elderly patients selected for transcatheter aortic valve implantation (TAVI). Therapeutic strategies to manage concomitant obstructive CAD are therefore an important consideration in the overall management of patients with severe aortic stenosis (AS) undergoing TAVI. Conventional surgical aortic valve replacement and coronary artery bypass grafting is the treatment of choice for low and intermediate risk patients with symptomatic severe AS and concomitant obstructive CAD. However, TAVI and percutaneous coronary intervention (PCI) are viable alternative options for high-risk or inoperable patients presenting with symptomatic severe AS. PCI has been shown to be feasible and safe in selected high-risk or inoperable patients with symptomatic severe AS. However, the optimal timing of PCI relative to the TAVI procedure has been a subject of debate. The most frequent approch is staged PCI typically performed a few weeks prior to TAVI. However, concomitant PCI has also been shown to be a feasible and safe approach, particularly in patients with a low level of CAD complexity and an absence of severe renal impairment. Conversely, staged PCI should be considered in patients with higher degrees of CAD complexity, particularly in the presence of severe renal impairment. The aim of the present review is to discuss the safety and feasibility of performing PCI in elderly patients with severe AS and the optimal timing of PCI relative to the TAVI procedure using the most up-to-date available evidence.

Entities:  

Mesh:

Year:  2014        PMID: 25274461

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  5 in total

1.  A Glimpse into the Future: In 2020, Which Patients will Undergo TAVI or SAVR?

Authors:  Crochan J O'Sullivan; Peter Wenaweser
Journal:  Interv Cardiol       Date:  2017-05

2.  Impact of Mitral Regurgitation on Clinical Outcomes After Transcatheter Aortic Valve Implantation.

Authors:  Crochan J O'Sullivan; David Tüller; Rainer Zbinden; Franz R Eberli
Journal:  Interv Cardiol       Date:  2016-05

3.  Successful percutaneous coronary intervention after transcatheter aortic valve implantation with CoreValve bioprosthesis.

Authors:  Zenon Huczek; Kajetan Grodecki; Bartosz Rymuza; Janusz Kochman; Krzysztof J Filipiak; Grzegorz Opolski
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-05-11       Impact factor: 1.426

Review 4.  Bioprosthetic Aortic Valve Replacement in <50 Years Old Patients - Where is the Evidence?

Authors:  Amer Harky; Michael Man Yuen Suen; Chris Ho Ming Wong; Abdul Rahman Maaliki; Mohamad Bashir
Journal:  Braz J Cardiovasc Surg       Date:  2019-12-01

5.  Outcomes comparison of different surgical strategies for the management of severe aortic valve stenosis: study protocol of a prospective multicentre European registry (E-AVR registry).

Authors:  Francesco Onorati; Riccardo Gherli; Giovanni Mariscalco; Evaldas Girdauskas; Eduardo Quintana; Francesco Santini; Marisa De Feo; Sandro Sponga; Piergiorgio Tozzi; Mohamad Bashir; Andrea Perrotti; Aniello Pappalardo; Vito Giovanni Ruggieri; Giuseppe Santarpino; Mauro Rinaldi; Silva Ronaldo; Francesco Nicolini
Journal:  BMJ Open       Date:  2018-02-10       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.